Glatiramer acetate: A review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

CNS Drugs

Volumn 27, Issue 11, 2013, Pages 971-988

  Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; N ACETYLASPARTIC ACID; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

AIRWAY CONSTRICTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BRAIN SIZE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CLINICALLY DEFINITE MULTIPLE SCLEROSIS; COMPASSIONATE USE; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ERYTHEMA; EXPANDED DISABILITY STATUS SCALE; FEVER; FLUSHING; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HAIR LOSS; HEADACHE; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSOMNIA; KIDNEY DYSFUNCTION; LIPOATROPHY; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; LONG TERM CARE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RELAPSE; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SKIN INDURATION; SKIN IRRITATION; SKIN NECROSIS; SKIN SWELLING; SPONTANEOUS ABORTION; THORAX PAIN; URTICARIA; VASODILATATION;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PEPTIDES; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 84887109054     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0117-3     Document Type: Review

References (99)

1. World Health Organization. Atlas: multiple sclerosis resources in the world. 2008. http://www.who.int/mental-health/neurology/Atlas-MS-WEB.pdf. Accessed 15 Jul 2013.
2. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180-8.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938-52.
4. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445-68.
5. Stuve O, Bennett JL, Hemmer B, et al. Pharmacological treatment of early multiple sclerosis. Drugs. 2008;68(1):73-83.
6. Lipsy RJ, Schapiro RT, Prostko CR. Current and future directions of MS management: key considerations for managed care pharmacists. J Manag Care Pharm. 2009;15(9 Suppl a):S2-15.
7. Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag. 2010;6:153-72.
8. Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25(5):401-14.
9. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010;70(12):1545-77.
10. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12(5):543-53.
11. Jalilian B, Einarsson HB, Vorup-Jensen T. Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? Int J Mol Sci. 2012;13(11):14579-605.
12. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol. 2008;255(Suppl 1):26-36.
13. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825-50.
14. Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS: fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36(3):245-53.
15. Tumani H, Kassubek J, Hijazi M, et al. Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol. 2011;65(3):164-9.
16. Oreja-Guevara C, Ramos-Cejudo J, Aroeira LS, et al. TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab. BMC Neurol. 2012;12:95.
17. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA. 2000;97(13):7452-7.
18. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler. 2001;7(4):209-19.
19. Chen M, Conway K, Johnson KP, et al. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci. 2002;201(1-2):71-7.
20. ®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105(7):967-76.
21. ®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1998;92(1-2):113-21.
22. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172(11):7144-53.
23. Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exper Immunol. 2006;143(2):357-62.
24. Gilli F, Navone ND, Valentino P, et al. Classification of individuals based on ex-vivo glatiramer acetate-induced interferon- and interleukin-4 response. Mult Scler. 2012;18(10):1484-92.
25. Valenzuela RM, Costello K, Chen M, et al. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler. 2007;13(6):754-62.
26. Chiarini M, Sottini A, Ghidini C, et al. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Mult Scler. 2010;16(2):218-27.
27. Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259(6):1199-205.
28. Sellebjerg F, Hesse D, Limborg S, et al. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Mult Scler. 2013;19(2):179-87.
29. Pul R, Morbiducci F, Skuljec J, et al. Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients. PLoS ONE. 2012;7(12):e51867.
30. Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA. 2009;106(11):4355-9.
31. Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain. 2006;129(Pt 5):1293-305.
32. Hoglund RA, Holmoy T, Harbo HF, et al. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA). PLoS ONE. 2013;8(4):e62237.
33. Hestvik AL, Skorstad G, Price DA, et al. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler. 2008;14(6):749-58.
34. Teva Neuroscience Inc. COPAXONE (glatiramer acetate) solution for subcutaneous injection: USA prescribing information 2012. http://copaxone.com/ pdfs/PrescribingInformation.aspx. Accessed 16 Sep 2013.
35. Sellebjerg F, Hedegaard CJ, Krakauer M, et al. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Mult Scler. 2012;18(3):305-13.
36. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler. 2003;9(6):592-9.
37. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290-7.
38. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes. Neurology. 2001;57(4):731-3.
39. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-11.
40. Arnold DL, Campagnolo D, Panitch H, et al. Glatirmaer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol. 2008;255:1473-8.
41. Waschbisch A, Atiya M, Linker RA, et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS ONE. 2011;6(9):e24604.
42. Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers. 2009;27(2):63-73.
43. Bakshi S, Chalifa-Caspi V, Plaschkes I, et al. Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opin Ther Targets. 2013;17(4):351-62.
44. Teva Pharmaceuticals Ltd. Summary of product characteristics: copaxone 20 mg/mL, solution for injection, pre-filled syringe. 2013. http://www.medicines. org.uk/emc/medicine/17516/SPC/Copaxone+20mg+ml%2c+Solution+For+Injection%2c+Pre- Filled+Syringe/. Accessed 16 Sep 2013.
45. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
46. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-14.
47. O'Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97.
48. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72:1976-83.
49. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 2003;9(6):585-91.
50. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50(3):701-8.
51. Wolinsky JS, Narayana PA, Johnson KP, et al. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler. 2001;7:33-41.
52. Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand. 2005;111(1):42-7.
53. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12(3):309-20.
54. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342-50.
55. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000;54(4):813-7.
56. Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci. 2007;255(1-2):57-63.
57. Wolinsky JS, Comi G, Filippi M, et al. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology. 2002;59(8):1284-6.
58. Stourac P, Praksova P, Kontrova I, et al. Efficacy of glatiramer acetate in Czech multicentre observational study in the period 2006-2010 [abstract no. P1041]. Mult Scler. 2011;17(Suppl):S475.
59. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ. 2010;13(3):464-71.
60. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [Erratum appears in N Engl J Med. 2012 Oct 25;367(17):1673]. N Engl J Med. 2012;367(12):1087-97.
61. Ziemssen T, Hoffman J, Apfel R, et al. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes. 2008;6:67.
62. Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010;8:133.
63. Ziemssen T, Carra A, De Klippel N, et al. Insights from the Coptimize study: characteristics of relapsing-remitting multiple sclerosis patients switching to glatiramer acetate [abstract no. P510]. Mult Scler. 2011;17:S218.
64. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-β-1b-treated multiple sclerosis patients. Acta Neurol Scand. 2006;113(6):378-86.
65. Meca-Lallana JE, de Mingo-Casado P, Amorin-Diaz M, et al. Effects of glatiramer acetate on spasticity in previously interferon-β-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Clin Ther. 2010;32(6):1061-6.
66. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87-94.
67. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001;124(9):1803-12.
68. Filippi M, Rocca MA, Camesasca F, et al. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011;76(14):1222-8.
69. Cadavid D, Cheriyan J, Skurnick J, et al. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009;80(12):1337-43.
70. Vollmer T, Panitch H, Bar-Or A, et al. Galtiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14(5):663-70.
71. Lindsey JW, Scott TF, Lynch SG, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord. 2012;1(2):81-6.
72. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327-40.
73. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806-12.
74. Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19(8):1074-83.
75. Arnold DL, Narayana S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260:1901-6.
76. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257(12):2020-3.
77. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124.
78. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs. 2010;24(11):969-76.
79. Teva Pharmaceuticals Ltd. Public Assessment Report Mutual Recognition Procedure: copaxone 20 mg/mL soultion for injection, prefilled syringe. 2008. http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con025676. pdf. Accessed 27 May 2013.
80. National Collaborating Centre for Chronic Conditions. Multiple sclerosis: national clinical guideline for the diagnosis and management in primary and secondary care. 2004. http://www.ncbi.nlm.nih.gov/books/NBK48919/pdf/TOC.pdf. Accessed 16 Jul 2013.
81. National Institute for Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care (Clinical Guideline 8). 2003. http://www.nice.org.uk/nicemedia/pdf/cg008guidance.pdf. Accessed 17 Jul 2013.
82. National Clinical Advisory Board of the National Multiple Sclerosis Society. Treatment recommendations for physicians: disease management consensus statement. 2007. http://www.nationalmssociety.org/about-multiple-sclerosis/ treatments/download.aspx?id=8. Accessed 16 Jul 2013.
83. Association of British Neurologists. Association of British Neurologists: revised (2009) guidelines for prescribing in multiple sclerosis. 2009. http://www.theabn.org/abn/userfiles/file/abn-ms-guidelines-2009-final.pdf. Accessed 16 Jul 2013.
84. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-78.
85. Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25(8):673-98.
86. Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: relevance of sphingosine 1-phosphate receptor modulator therapy. Neurology. 2011;76(8 Suppl 3):S28-37.
87. European Medicines Agency. Gilenya: summary of product characteristics 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002202/WC500104528.pdf. Accessed 22 Jul 2013.
88. Novartis Pharmaceuticals Corporation. Gilenya™: USA prescribing information. 2012. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis. com/product/pi/pdf/gilenya.pdf. Accessed 22 Jul 2013.
89. USA Food and Drug Administration. FDA approves new multiple sclerosis treatment: Tecfidera. 2013. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm345528.htm. Accessed 23 Jul 2013.
90. European Medicines Agency. Summary of opinion (initial authorisation): tecfidera (dimethyl fumarate). 2013. http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/002601/smops/Positive/human-smop-000498. jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human. Accessed 23 Jul 2013.
91. European Medicines Agency. Summary of opinion (initial authorisation): Aubagio (teriflunomide). 2013. http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/human/002514/WC500144913.pdf. Accessed 23 Jul 2013.
92. USA Food and Drug Administration. FDA approves new multiple sclerosis treatment: Aubagio (teriflunomide). 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/Summary-of-opinion-Initial-authorisation/human/002514/ WC500144913.pdf. Accessed 23 Jul 2013.
93. Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther. 2011;28(9):761-75.
94. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
95. Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurol. 2008;71(24 Suppl 3):S3-7.
96. Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-13.
97. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70(13):1677-91.
98. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-61.
99. Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12(5):657-65.